DOCSLIB.ORG

Characterization of 8-OH-DPAT-Induced Hypothermia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Characterization of 8-OH-DPAT-Induced Hypothermia Br. J. Pharmacol. (1992), 107, 15-21 '." Macmillan Press Ltd, 1992 Characterization of 8-OH-DPAT-induced hypothermia in mice as a 5-HTlA autoreceptor response and its evaluation as a model to selectively identify antidepressants 'Keith F. Martin, Ian Phillips, Mitchell Hearson, Michael R. Prow & David J. Heal Boots Pharmaceuticals Research Department, Nottingham NG2 3AA 1 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) dose-dependently induced hypothermia in mice. 2 The 5-HTIA receptor partial agonists, buspirone, gepirone and ipsapirone, also dose-dependently induced hypothermia. 3 The 8-OH-DPAT temperature response was antagonized by the 5-HT, receptor antagonists quipazine (2mg kg', i.p.), (±)-propranolol (10mgkg-', i.p.). (±)-pindolol (5mgkg-', i.p.), spiroxa- trine (0.5 mg kg-', i.p.) and metitepine (0.05 mg kg-', i.p.), but not by 5-HT2 (ketanserin) or 5-HT3 (MDL 72222, GR 38032F) receptor antagonists. 4 The response was also antagonized by the dopamine D2 receptor antagonists, haloperidol and BRL 34778. No other catecholamine or muscarinic receptors were involved in mediating the response. 5 Destruction of 5-hydroxytryptamine (5-HT)-containing neurones with the neurotoxin, 5,7- dihydroxytryptamine (75 bg, i.c.v.), abolished the response to 8-OH-DPAT indicating that the 5-HTIA receptors involved were located on 5-HT neurones. 6 Chronic antidepressant treatment down-regulated this 8-OH-DPAT response. In addition, chronic administration of anxiolytics and neuroleptics was also effective in this respect. Down-regulation was also observed following repeated administration of 8-OH-DPAT (0.5 mg kg-', s.c.), (± )-pindolol (10mg kg-', i.p.) and ketanserin (0.5 mg kg-', i.p.). 7 In conclusion, these data confirm that 8-OH-DPAT-induced hypothermia is mediated by 5-HTIA autoreceptors. They also indicate that the response involves D2 receptors. The present study also shows that a wide range of antidepressant drugs down-regulate this response although this property is not restricted to antidepressant treatments. Therefore, care should be exercised when interpreting data from this paradigm. Keywords: 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT); hypothermia; mice; antidepressants; 5-HTIA receptors Introduction In 1983, Middlemiss & Fozard showed that 8-hydroxy-2-(di- Goodwin et al. (1985b) have reported that 8-OH-DPAT- n-propylamino)tetralin (8-OH-DPAT) was a selective agonist induced hypothermia in mice was selectively attenuated after at 5-HTIA receptors. Subsequently, it was found that repeated administration of antidepressant drugs and electro- peripheral administration of 8-OH-DPAT induced hypother- convulsive shock (ECS). However, as the types of antidepres- mia in mice and rats (Hjorth, 1985; Goodwin & Green, 1985; sant tested were limited and the authors failed to investigate Goodwin et al., 1985a; Gudelsky et al., 1986; Higgins et al., the effects of other psychotropic agents, their conclusion that 1988; Wozniack et al., 1988). The studies in mice have shown this adaptation was specific to antidepressants required fur- that this response is dose-dependent and sigmoidal (e.g. ther confirmation. Goodwin et al., 1985a). Pharmacological evaluation of the The aims of the work described here were two fold: first, to hypothermic response to 8-OH-DPAT led these authors to extend the pharmacological characterization of the 8-OH- suggest that it was specifically mediated by 5-HTIA receptors DPAT-induced hypothermia in mice and second, to deter- located on 5-hydroxytryptaminergic neurones. Goodwin and mine whether the adaptive down-regulation of this response his coworkers based this hypothesis on inhibition of the was specific to antidepressant treatment. response by ipsapirone (Goodwin et al., 1986), a partial agonist at 5-HTIA receptors (Martin & Mason, 1986), low doses of quipazine (Goodwin et al., 1985a) and abolition of Methods the response by destruction of 5-HT neurones (Goodwin et al., 1985a). However, these authors were unable to prevent Animals the effects of 8-OH-DPAT with a range of other 5-HTI-like receptor antagonists. Furthermore, haloperidol, a potent D2 Adult male C57/Bl/601a mice (Olac, Bicester) weighing dopamine receptor antagonist, was also found to inhibit this 25-30 g were used throughout this study. They were housed response (Goodwin et al., 1985a). The data suggest, there- in groups of 10 on a 12:12 h light:dark cycle (lights on fore, that the pharmacology of 8-OH-DPAT-induced hypo- 07 h 00 min) and had free access to food and water. The thermia in mice may not be as straight-forward as first ambient temperature was maintained at 20± 10C and thought. humidity was approximately 50%. Agonist studies Core temperature was measured by inserting the probe of a Author for correspondence. digital thermometer approximately 2.5 cm into the rectum 16 K.F. MARTIN et al. while lightly restraining the animal 10 min prior to (t- o), All drugs were dissolved in 0.9% saline and injected intra- immediately before (t0) and 20 min after (t20) an s.c. injection peritoneally (i.p.) with the exception of 8-OH-DPAT, buspirone, of saline or 5-HTlA receptor agonist and the difference in gepirone and ipsapirone which were given subcutaneously (s.c.). temperature between t0 and t20 was calculated. Antagonist studies Results Animals received either saline (10mgkg-', s.c.) or 8-OH- Effects ofS-HTIA receptor agonists on rectal temperature DPAT (0.5 mg kg-', s.c.) 30 min after an i.p. injection of saline or antagonist. Rectal temperature was measured When mice were injected with increasing doses of 8-OH- immediately before the first injection (t 30) and prior to the DPAT (0.05 to 5.0 mg kg-', s.c.), this 5-HTIA receptor second injection of saline or 8-OH-DPAT (to). A further agonist produced a dose-dependent decrease in temperature measurement was taken 20 min after the second injection (Figure 1). Time-course studies showed that the maximum (t20). The difference in temperature between to and t20 was hypothermic effect was observed 20 min after 8-OH-DPAT calculated. (data not shown). Similarly, the 5-HTIA receptor partial agonists, buspirone, gepirone and ipsapirone, also dose- Effect of chonic drug treatments dependently induced hypothermia in mice (Figure 1). Groups of mice received either 14 daily injections (i.p.) of Effects of5-HT receptor antagonists drugs or saline. The temperature decrease following an injec- tion of 8-OH-DPAT (0.5 mg kg-', s.c.) was determined 24 h The putative 5-HTl/5-HTIA receptor antagonists quipazine after the first and last treatments. (2mg kg-'), (±)-propranolol (10 and 20mg kg-'), (+)- pindolol (5 and 10 mg kg-'), spiroxatrine (0.5 and 5 mg kg-') 5-Hydroxytryptamine-containing neurone lesioning studies and metitepine (0.05 mg kg-') significantly attenuated the hypothermic response to 8-OH-DPAT (Table 1). Only quipa- The 5-HT neurotoxin, 5,7-dihydroxytryptamine (5,7-DHT; zine had any significant effect (a small increase cf. control) 75 pg) or saline-ascorbate (4 fl) was injected i.c.v. into when given alone (Table 1). Metitepine antagonized the re- halothane anaesthetized mice, pretreated with desipramine sponse at a dose of 0.05 mg kg-', which itself had no effect on (5 mg kg-', i.p.) to protect noradrenergic neurones, by the core temperature. However at a dose of 0.5 mg kg-', method of Heal (1984). The temperature response to 8-OH- metitepine caused a marked reduction in temperature DPAT (0.5 mg kg-1, i.p.) was measured seven days later as (3.85 ± 0.79°C; P <0.001). There was no further fall in described above. temperature induced by 8-OH-DPAT. The non-selective 5-HT receptor antagonist, metergoline had similar effects (Table 1). Noradrenaline-containing neurone lesioning studies Ketanserin (0.2 mg kg-'), a 5-HT2/5-HT,c receptor antagonist, did not significantly alter body temperature itself, Mice were given an i.p. injection of N-(2-chloroethyl)-N- nor did it affect the hypothermia induced by 8-OH-DPAT ethyl-2-bromobenzylamine (DSP-4, 100 mg kg-') 30 min (Table 1). after zimeldine (5 mg kg-', i.p.). Seven days later this proce- At moderate doses, the 5-HT3 receptor antagonists, MDL dure was repeated. The temperature response to 8-OH-DPAT 72222 and GR 38032F, did not alter the temperature re- (0.5 mg kg-', i.p.) was measured 12 days after the first DSP-4 sponse to 8-OH-DPAT (Table 1). injection as described above. Effects of catecholamine and muscarinic receptor Statistics antagonists Data were analysed by Student's unpaired t test and the null The ax-adrenoceptor antagonist, prazosin (0.1 mg kg-') did hypothesis was rejected when P <0.05. However, when two not attenuate the response to 8-OH-DPAT (0.5 mg kg-') treatment groups were compared with a single control group, (Table 2). However, at high dose (1 mg kg-'), it induced a the level of significance for rejection of the null hypothesis marked fall in core temperature itself; this was not altered by was set at P<0.01. 8-OH-DPAT (Table 2). The M2-adrenoceptor antagonist, Drugs 3- The following drugs were used (abbreviation if any and source shown in parentheses): N-(2-chloroethyl)-N-ethyl-2- co bromobenzylamine (DSP-4), 8-hydroxy-2(di-n-propyl- amino)tetralin HBr (8-OH-DPAT); ondansetron (GR 38032F), laH,3ax,5aH-tropan-3-yl-3,5-dichlorobenzoate (MDL 72222), (+ )-7-chloro-8-hydroxy-3-methyl-l-phenyl-2,3,4,5- tetrahydro-lH-3-benzazepine maleate (SCH 23390), spiroxat- 0 rine (Research Biochemicals Inc.), dothiepin HCl2, gepirone (HCl)2, ipsapirone (HCI)2, sibutramine HCI (Boots Phar- maceuticals), zimeldine (HCl)2 (Astra), exo-N-(9-[(4- fluorophenyl)methyl)-9-azabicyclo [3.3.1]non-3-yl)-4-amino-5- chloro-2-methoxybenzamide (BRL 34778) (Beecham), map- rotiline (Ciba-Geigy), metitepine, metergoline (Farmitalia), 0.05 0.5 5 0.1 1 10 0.1 1 10 0.1 1 10 erythro-( ± )-I-(7-methylindan-4-yloxy)-3-isopropylaminobutan 8-OH-DPAT Buspirone Gepirone.
Load more

Recommended publications
  • TABLE 1 Studies of Antagonist Activity in Constitutively Active
    TABLE 1 Studies of antagonist activity in constitutively active receptors systems shown to demonstrate inverse agonism for at least one ligand Targets are natural Gs and constitutively active mutants (CAM) of GPCRs. Of 380 antagonists, 85% of the ligands demonstrate inverse agonism. Receptor Neutral Antagonist Inverse Agonist Reference Human β2-adrenergic Dichloroisoproterenol, pindolol, labetolol, timolol, Chidiac et al., 1996; Azzi et alprenolol, propranolol, ICI 118,551, cyanopindolol al., 2001 Turkey erythrocyte β-adrenergic Propranolol, pindolol Gotze et al., 1994 Human β2-adrenergic (CAM) Propranolol Betaxolol, ICI 118,551, sotalol, timolol Samama et al., 1994; Stevens and Milligan, 1998 Human/guinea pig β1-adrenergic Atenolol, propranolol Mewes et al., 1993 Human β1-adrenergic Carvedilol CGP20712A, metoprolol, bisoprolol Engelhardt et al., 2001 Rat α2D-adrenergic Rauwolscine, yohimbine, WB 4101, idazoxan, Tian et al., 1994 phentolamine, Human α2A-adrenergic Napthazoline, Rauwolscine, idazoxan, altipamezole, levomedetomidine, Jansson et al., 1998; Pauwels MPV-2088 (–)RX811059, RX 831003 et al., 2002 Human α2C-adrenergic RX821002, yohimbine Cayla et al., 1999 Human α2D-adrenergic Prazosin McCune et al., 2000 Rat α2-adrenoceptor MK912 RX821002 Murrin et al., 2000 Porcine α2A adrenoceptor (CAM- Idazoxan Rauwolscine, yohimbine, RX821002, MK912, Wade et al., 2001 T373K) phentolamine Human α2A-adrenoceptor (CAM) Dexefaroxan, (+)RX811059, (–)RX811059, RS15385, yohimbine, Pauwels et al., 2000 atipamezole fluparoxan, WB 4101 Hamster α1B-adrenergic
    [Show full text]
  • Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation
    www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.
    [Show full text]
  • 4 Supplementary File
    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Hallucinogens: an Update
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Hallucinogens: An Update 146 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Hallucinogens: An Update Editors: Geraline C. Lin, Ph.D. National Institute on Drug Abuse Richard A. Glennon, Ph.D. Virginia Commonwealth University NIDA Research Monograph 146 1994 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Hallucinogens: An Update” held on July 13-14, 1992. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • (ESI) for Integrative Biology. This Journal Is © the Royal Society of Chemistry 2017
    Electronic Supplementary Material (ESI) for Integrative Biology. This journal is © The Royal Society of Chemistry 2017 Table 1 Enriched GO terms with p-value ≤ 0.05 corresponding to the over-expressed genes upon perturbation with the lung-toxic compounds. Terms with corrected p-value less than 0.001 are shown in bold. GO:0043067 regulation of programmed GO:0010941 regulation of cell death cell death GO:0042981 regulation of apoptosis GO:0010033 response to organic sub- stance GO:0043068 positive regulation of pro- GO:0010942 positive regulation of cell grammed cell death death GO:0006357 regulation of transcription GO:0043065 positive regulation of apop- from RNA polymerase II promoter tosis GO:0010035 response to inorganic sub- GO:0043066 negative regulation of stance apoptosis GO:0043069 negative regulation of pro- GO:0060548 negative regulation of cell death grammed cell death GO:0016044 membrane organization GO:0042592 homeostatic process GO:0010629 negative regulation of gene ex- GO:0001568 blood vessel development pression GO:0051172 negative regulation of nitrogen GO:0006468 protein amino acid phosphoryla- compound metabolic process tion GO:0070482 response to oxygen levels GO:0045892 negative regulation of transcrip- tion, DNA-dependent GO:0001944 vasculature development GO:0046907 intracellular transport GO:0008202 steroid metabolic process GO:0045934 negative regulation of nucle- obase, nucleoside, nucleotide and nucleic acid metabolic process GO:0006917 induction of apoptosis GO:0016481 negative regulation of transcrip- tion GO:0016125 sterol metabolic process GO:0012502 induction of programmed cell death GO:0001666 response to hypoxia GO:0051253 negative regulation of RNA metabolic process GO:0008203 cholesterol metabolic process GO:0010551 regulation of specific transcrip- tion from RNA polymerase II promoter 1 Table 2 Enriched GO terms with p-value ≤ 0.05 corresponding to the under-expressed genes upon perturbation with the lung-toxic compounds.
    [Show full text]
  • Structure and Ligand Binding Properties at The
    TURUN YLIOPISTON JULKAISUJA ANNALES UNIVERSITATIS TURKUENSIS TURUN YLIOPISTON JULKAISUJA ANNALES UNIVERSITATIS TURKUENSIS SARJA - SER. D OSA - TOM. 962 SARJA - SER. D OSA - TOM. XXX MEDICA - ODONTOLOGICA MEDICA - ODONTOLOGICA 2-ADRENOCEPTORS: STRUCTURE α2-ADRENOCEPTORS: STRUCTURE AND LIGAND BINDING PROPERTIES AND LIGAND BINDING PROPERTIES AT THE MOLECULAR LEVEL AT THE MOLECULAR LEVEL by by Jonne M.M. Laurila Jonne M.M. Laurila TURUN YLIOPISTO Turku 2011 TURUN YLIOPISTO UNIVERSITY OF TURKU Turku 2011 From the Institute of Biomedicine, From the Institute of Biomedicine, Department of Pharmacology, Drug Development and Therapeutics Department of Pharmacology, Drug Development and Therapeutics University of Turku University of Turku Turku, Finland Turku, Finland Supervised by Supervised by Professor Mika Scheinin, MD, PhD Professor Mika Scheinin, MD, PhD Department of Pharmacology, Drug Development and Therapeutics Department of Pharmacology, Drug Development and Therapeutics University of Turku University of Turku Turku, Finland Turku, Finland Reviewed by Reviewed by Docent Jarmo T. Laitinen, PhD Docent Jarmo T. Laitinen, PhD Institute of Biomedicine/Physiology Institute of Biomedicine/Physiology University of Eastern Finland University of Eastern Finland Kuopio, Finland Kuopio, Finland and and Docent Ulla Petäjä-Repo, PhD Docent Ulla Petäjä-Repo, PhD Institute of Biomedicine/Department of Anatomy and Cell Biology Institute of Biomedicine/Department of Anatomy and Cell Biology University of Oulu University of Oulu Oulu, Finland Oulu, Finland
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • WO 2016/106182 Al 30 June 2016 (30.06.2016) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/106182 Al 30 June 2016 (30.06.2016) W P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61N 1/04 (2006.01) A61N 1/372 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61N 1/08 (2006.01) A61K 31/435 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61N 1/18 (2006.01) A61K 31/428 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, A61N 1/24 (2006.01) A61K 31/137 (2006.01) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, A61N 1/32 (2006.01) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (21) International Application Number: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, PCT/US20 15/0670 17 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (22) International Filing Date: (84) Designated States (unless otherwise indicated, for every 2 1 December 2015 (21 .12.2015) kind of regional protection available): ARIPO (BW, GH, (25) Filing Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (26) Publication Language: English TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (30) Priority Data: DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 62/096,226 23 December 2014 (23.
    [Show full text]
  • Drug Repositioning for Seven Psychiatric Disorders
    bioRxiv preprint doi: https://doi.org/10.1101/096503; this version posted December 23, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. When GWAS meets the Connectivity Map: drug repositioning for seven psychiatric disorders Hon-Cheong So1,2*, Carlos K.L. Chau1, Wan-To Chiu3, Kin-Sang Ho3, Cho-Pong Lo3, Stephanie Ho-Yue Yim4 and Pak C. Sham5,6,7,8 1School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong 2KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research of Common Diseases, Kunming Zoology Institute of Zoology and The Chinese University of Hong Kong 3Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong 4Univeristy of Exeter Medical School, United Kingdom 5Department of Psychiatry, University of Hong Kong, Pokfulam, Hong Kong 6Centre for Genomic Sciences, University of Hong Kong, Pokfulam, Hong Kong 7State Key Laboratory for Cognitive and Brain Sciences, University of Hong Kong, Pokfulam, Hong Kong 8Centre for Reproduction, Development and Growth, University of Hong Kong, Pokfulam, Hong Kong *Correspondence to: Hon-Cheong So, School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong Email: [email protected] (Submitted to bioRxiv on 23 Dec 2016) 1 bioRxiv preprint doi: https://doi.org/10.1101/096503; this version posted December 23, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Our knowledge of disease genetics has advanced rapidly during the past decade, with the advent of high-throughput genotyping technologies such as genome-wide association studies (GWAS).
    [Show full text]